Skip to search formSkip to main contentSkip to account menu

RoActemra®

Known as: RoActemra 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of… 
2018
2018
Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition
ABSTRACT K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is… 
Review
2017
Review
2017
Tocilizumab: A Review in Rheumatoid Arthritis
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in… 
Review
2016
Review
2016
The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
BACKGROUND Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by… 
Review
2013
Review
2013
A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high… 
Review
2013
Review
2013
Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis
Tocilizumab (Actemra®, RoActemra®) is a humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist… 
Highly Cited
2012
Highly Cited
2012
Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?
To the Editor: Anti-interleukin 6 receptor (anti-IL-6R) antibodies have been effective in experimental models of autoimmune… 
Review
2011
Review
2011
Tocilizumab: A Novel Humanized Anti-Interleukin 6 Receptor Antibody for the Treatment of Patients with Rheumatoid Arthritis
  • R. Alten
  • Therapeutic Advances in Musculoskeletal Disease
  • 2011
  • Corpus ID: 8591212
Tocilizumab (TCZ; RoActemra® or Actemra®) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6… 
Review
2009
Review
2009
Tocilizumab: a review of its use in the management of rheumatoid arthritis.
Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor… 
Review
2009
Review
2009
▼Tocilizumab for rheumatoid arthritis
▼Tocilizumab (RoActemra – Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)